LU90842I2 - Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90842I2
LU90842I2 LU90842C LU90842C LU90842I2 LU 90842 I2 LU90842 I2 LU 90842I2 LU 90842 C LU90842 C LU 90842C LU 90842 C LU90842 C LU 90842C LU 90842 I2 LU90842 I2 LU 90842I2
Authority
LU
Luxembourg
Prior art keywords
mabcampath
alemtuzumab
pharmaceutically acceptable
acceptable derivatives
framework regions
Prior art date
Application number
LU90842C
Other languages
English (en)
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803228A external-priority patent/GB8803228D0/en
Priority claimed from GB888804464A external-priority patent/GB8804464D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of LU90842I2 publication Critical patent/LU90842I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU90842C 1988-02-12 2001-09-26 Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables LU90842I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803228A GB8803228D0 (en) 1988-02-12 1988-02-12 Improvements in/relating to antibodies
GB888804464A GB8804464D0 (en) 1988-02-25 1988-02-25 Improvements in/relating to antibodies

Publications (1)

Publication Number Publication Date
LU90842I2 true LU90842I2 (fr) 2001-11-26

Family

ID=26293475

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90842C LU90842I2 (fr) 1988-02-12 2001-09-26 Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables

Country Status (13)

Country Link
EP (1) EP0328404B1 (fr)
JP (2) JP3121823B2 (fr)
AT (1) ATE95068T1 (fr)
AU (1) AU618989B2 (fr)
CA (1) CA1339198C (fr)
DE (2) DE10199051I2 (fr)
DK (1) DK174854B1 (fr)
ES (1) ES2059719T3 (fr)
GB (1) GB2216126B (fr)
LU (1) LU90842I2 (fr)
NL (1) NL300067I1 (fr)
NZ (1) NZ227968A (fr)
WO (1) WO1989007452A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2066720A1 (fr) * 1989-09-19 1991-03-20 David M. Knight Methode d'amelioration de la production d'anticorps monoclonaux humains
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
CA2082160C (fr) * 1991-03-06 2003-05-06 Mary M. Bendig Anticorps monoclonaux humanises et chimeriques
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
DK0671471T3 (da) * 1992-11-28 1999-10-18 Chemo Sero Therapeut Res Inst Fremgangsmåde til fremstilling af fremmed protein
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
CA2257357C (fr) 1996-06-07 2010-04-13 Neorx Corporation Anticorps humanises a glycosylation modifiee
WO2003009740A2 (fr) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
EP1618891A1 (fr) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Methode d'induction de differenciation et de proliferation de cellules t regulatrices par un anticorps anti-cd52 et composition medicinale associee
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
CA2565259A1 (fr) 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP2791170A1 (fr) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Composés et procédés pour traiter des maladies inflammatoires
WO2018174274A1 (fr) 2017-03-24 2018-09-27 全薬工業株式会社 ANTICORPS BISPÉCIFIQUE ANTI-IgM/ANTIGÈNE DE SURFACE DE LYMPHOCYTE B

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
GB8902978D0 (en) 1989-03-30
CA1339198C (fr) 1997-08-05
AU618989B2 (en) 1992-01-16
GB2216126A (en) 1989-10-04
JP3121823B2 (ja) 2001-01-09
EP0328404B1 (fr) 1993-09-29
ES2059719T3 (es) 1994-11-16
DE10199051I1 (de) 2002-01-10
EP0328404A1 (fr) 1989-08-16
DK502189A (da) 1989-10-12
DK174854B1 (da) 2003-12-22
AU3062689A (en) 1989-09-06
JPH02503514A (ja) 1990-10-25
JPH11228600A (ja) 1999-08-24
ATE95068T1 (de) 1993-10-15
NZ227968A (en) 1992-01-29
DE68909441D1 (de) 1993-11-04
WO1989007452A1 (fr) 1989-08-24
GB2216126B (en) 1992-06-03
DE68909441T2 (de) 1994-02-10
DK502189D0 (da) 1989-10-10
NL300067I1 (nl) 2001-12-01
DE10199051I2 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
LU90842I2 (fr) Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
FI20030933A7 (fi) 1,3-oksatiolaani ja menetelmä sen valmistamiseksi
FI925098A7 (fi) Ihmisen papilloomavirusten 1,5,6,8,11,16,18,31,33 ja 56 synteettisiä p eptidejä, jotka ovat käyttökelpoisia immunoanalyysissä diagnostisiin t arkoituksiin
FR2691602B1 (fr) Accélérateur linéaire de protons à focalisation améliorée et impédance shunt élevée.
DE69116398D1 (de) Basenbeständige Fluorelastomere mit verbesserter Verarbeitbarkeit und Härtbarkeit
IT8967343A0 (it) Anticorpo umano monoclonale ed ibridoma che produce il medesimo
KR910002005A (ko) 바이폴라트랜지스터와 그 제조방법
DE68908880D1 (de) Äthanolbrennstoff und dessen verwendung als dieselbrennstoff.
DK0583281T3 (da) Modgift - immunsera
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
ATE109834T1 (de) Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2.
IT1229135B (it) Copolimeri transesterificati dell'anidride maleica, particolarmente utili nel campo della detergenza.
DE69013372D1 (de) Ori-gehemmte und niederschlagsbeständige Motorkraftstoffzusammensetzung.
DE68924495D1 (de) Halbleiter-Bauelement mit verbesserter Gate-Kapazität und dessen Herstellungsverfahren.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.
FI894552A0 (fi) Anordning i gasregulator.
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
FI952779A7 (fi) HCV:n C33-alueen peptidejä, vasta-aineita niitä vastaan ja menetelmiä HCV:n toteamiseksi
RU1808414C (ru) Устройство дл сортировки и перемещени сыпучих материалов
MX9100291A (es) Nuevos derivados de la 6-metil 19-nor progesterona,substituidos en 3 y su procedimiento de obtencion
SU640010A1 (ru) Винтовой замок
KR950032244U (ko) 대변감지가 부착된 기저귀